Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 Years on

International Journal of Clinical Practice

Volumn 62, Issue 3, 2008, Pages 480-484

  Usher Smith, J ^a,b   Ramsbottom, T ^c   Pearmain, H ^d   Kirby, M ^e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

^c The Surgery   (United Kingdom)

^d North Hertfordshire and Stevenage Primary Care Trust   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; CHOLESTEROL; LOSARTAN; RAMIPRIL; SIMVASTATIN;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL ASSESSMENT; MEDICAL RECORD REVIEW; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SIDE EFFECT; ST SEGMENT ELEVATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOSARTAN; MALE; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; TETRAZOLES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 38849113845     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01690.x     Document Type: Article

References (14)

1. Usher-Smith J, Ramsbottom T, Pearmain H et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007 61 : 15 23.
2. Baguet J-P, Nisse-Durgeat S, Mouret S et al. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract 2006 60 : 391 8.
3. Conlin P. Angiotensin II antagonists in the treatment of hypertension: more similarities than differences. J Clin Hypertens 2000 2 : 253 7.
4. Jones P, Davidson M, Stein E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 92 : 152 60.
5. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998 81 : 582 7.
6. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999 12 : 1181 7.
7. Nishimura T, Hashimoto J, Ohkubo T et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005 6 : 477 89.
8. Gradman AH, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999 1 : 52 7.
9. McElduff P, Lyratzopoulos G, Edwards R et al. Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK. Qual Saf Health Care 2004 13 : 191 7.
10. Volmink JA, Newton JN, Hicks NR et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Group. Heart 1998 80 : 40 4.
11. Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet 2007 369 : 27.
12. Moon J, Bogle R, Minas R. Statins audit: wrong question, wrong conclusions. Lancet 2007 369 : 640.
13. Hess G, Sanders K N, Hill J et al. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care 2007 13 : S80 5.
14. Phillips B, Roberts C, Rudolph AE et al. Switching statins: the impact on patient outcomes. Brit J Cardiol 2007 14 : 280 6.